Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US ...

Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy ...

Takeda will host an investor call on Sunday ... but it is to illustrate that as a global innovative pharmaceutical company, we have a very strong presence in the U.S., which is, by far today ...

As such, the Zacks rating upgrade for Takeda Pharmaceutical Co. is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration with Biological E. Clinical trials are underway, and the company aims to ...

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Takeda Pharmaceutical Co. imply an improvement in the company's underlying business. Investors should show ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...